Company profile for Tharimmune

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tharimmune, Inc. is a clinical-stage biotechnology company dedicated to the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company holds an exclusive global license for a clinical-stage asset designed to alleviate chronic pruritus (uncontrollable itching) associated with PBC, a rare and orphan liver disease lacking a known cure. Furthermore, Tharimmune's initial-stage immuno-oncology ...
Tharimmune, Inc. is a clinical-stage biotechnology company dedicated to the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company holds an exclusive global license for a clinical-stage asset designed to alleviate chronic pruritus (uncontrollable itching) associated with PBC, a rare and orphan liver disease lacking a known cure. Furthermore, Tharimmune's initial-stage immuno-oncology pipeline features innovative multi-specific antibodies that target distinct epitopes with novel mechanisms of action against established and validated targets in various solid tumors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1200 Route 22 East Suite 2000 Bridgewater, NJ 08807
Telephone
Telephone
+1 9089553140
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251212841716/en/Tharimmune-Inc.-Appoints-Jacob-Asbury-as-Chief-Financial-Officer-to-Advance-Canton-Coin-Treasury-Strategy

BUSINESSWIRE
12 Dec 2025

https://www.prnewswire.com/news-releases/tharimmune-receives-positive-fda-feedback-for-th104-prophylaxis-program-against-respiratory-depression-from-fentanyl-and-ultrapotent-opioids-302614477.html

PR NEWSWIRE
13 Nov 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/tharimmune-reports-pharmacokinetic-simulation-results-for-th104-as-prophylaxis-agains-1062977

ACCESSWIRE
20 Aug 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/tharimmune-secures-key-global-patents-for-th-104-laying-foundation-for-broader-indica-1060165

ACCESSWIRE
13 Aug 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/tharimmune-issues-comprehensive-corporate-update-including-lead-th104-as-critical-nat-1055981

ACCESSWIRE
04 Aug 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/tharimmune-announces-key-leadership-appointments-including-james-gordon-liddy-joining-1040297

ACCESSWIRE
17 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty